Abstract. One of the major challenges in neurodegenerative research is modeling systemic aging. Here, senescence-accelerated mice such as the multigenic SAMP8 (senescence accelerated prone 8) mice are useful as they are characterized by an early manifestation of senescence that includes a shortened lifespan and impaired brain and immune functions. While SAMP8 mice are widely used tools to address aging and neurodegenerative conditions such as Alzheimer's disease (AD), the underlying gene mutations are not known. To make the SAMP8 strain a more versatile and useful research tool, we performed exome sequencing, using SAMR1 (senescence accelerated mouse resistant 1) mice as controls. We identified 51 SNVs (single nucleotide variants) that discriminate SAMP8 from SAMR1 mice. Using the prediction tool Polyphen2, we were able to subdivide the SNVs into four categories: splice variants, probably damaging, possibly damaging, and benign. Of these genes, a significant fraction is predicted to be expressed in the brain. Our data present these genes for a more detailed analysis in aging and neurodegeneration studies. They underscore the usefulness of SAMP8 mice as an animal model to study fundamental mechanisms of both aging and the pathogenesis of AD.
INTRODUCTION
Aging is the major risk factor for a plethora of human diseases. This includes Alzheimer's disease (AD), a neurodegenerative disorder that is characterized by a progressive decline in memory and other cognitive 350 
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present in early-onset familial cases. The vast majority of AD cases, however, are of late onset and hence, transgenic models do not faithfully model these sporadic cases. Here, senescence-accelerated mice such as the SAMP8 (senescence accelerated prone 8) strain might be useful, as these mice display many features known to occur early in the pathogenesis of AD, such as increased oxidative stress and memory impairment [3] . SAMP8 mice are therefore an excellent model for studying the earliest neurodegenerative changes associated with AD, providing a more encompassing picture of human disease, a syndrome that is triggered by a combination of age-related events [4] .
Together with a series of related senescenceaccelerated mice, the SAMP8 strain was established around 1975 by conventional inbreeding of AKR/Jderived mice that displayed features of accelerated aging such as hair loss, reduced activity, shortened life expectancy, lordokyphosis (increased curvature of the spine), and periophthalmic (around the eye) problems [5] . Littermates of mice that did not show a senescence-associated phenotype were also inbred, and senescence-resistant, longer-lived SAMR mice were obtained of which SAMR1 (senescence accelerated mouse resistant 1) mice are commercially available. SAMP strains exhibit an early onset of age-related decline in the peripheral immunity such as thymic involution, loss of CD4(+) T cells, impaired helper T cell function, decreased antibodyforming capacity, dysfunction of antigen-presenting cells, decreased natural killer activity, increased autoantibodies, and susceptibility to viral infection [6] . SAMP8 mice have been extensively analyzed for cognitive functions [7] . Impairment of spatial memory is initiated at the age of four months, as shown by using various forms of water and radial arm mazes [8] [9] [10] . By employing the more sensitive radial arm water maze, impairments in spatial learning became evident as early as three months of age [11] . In measuring associative memories, fear conditioning or passive avoidance tasks are widely used [12, 13] . In SAMP8 mice, while associative learning as assessed in the fear conditioning-paradigm is not affected, both passive and active avoidance (i.e., learning to escape the environment in which the aversive stimulus has been received) are affected, with an age of onset as early as two months [14, 15] . SAMP8 mice are neuropathologically characterized by oxidative changes similar to those found in the AD brain [16] . For example, key enzymes that detoxify reactive oxygen species such as MnSOD, catalase or glutathione peroxidase are all decreased in SAMP8 compared to SAMR1 mice [17] [18] [19] . Increased lipid peroxidation and carbonyl damage is present as early as 2 months of age [20] . Furthermore, SAMP8 mice have an impaired glucose metabolism [21] , and reveal agedependent reductions of various receptors including for NMDA [22] . Because in the AD brain, deposition of A␤ leads to plaque formation and that of the microtubule-associated protein tau to tangle formation, these two process have been extensively analyzed in SAMP8 mice [23] . Tau was found to be hyperphosphorylated using a small set of phosphorylation site-specific antibodies, but tau filament formation and tangle formation has not been reported indicating that the SAMP8 mice present with an early rather than a more advanced tau pathology [23] . In phosphorylating tau and causing its aggregation [24] , studies in SAMP8 mice suggest a role for the kinases GSK3 and Cdk5 [25] . Staining with A␤-specific antibodies suggested A␤ deposition in the mice [26, 27] ; however because different from the human sequence of A␤PP, the murine protein lacks the amino acids that are required to generate A␤ in the first place, these deposits have been termed 'A␤-like' [26] . For A␤PP, age-related increases have been reported, both at the protein and mRNA level [28] [29] [30] . Finally, a glial pathology characterizes the aging brain and in particular, the AD brain, and not surprisingly, SAMP8 mice present with a marked astro-and microgliosis [30, 31] . These findings present SAMP8 mice as a suitable model for aging dementia, thereby complementing the existing transgenic mouse models.
However, a major drawback in making the best use of senescence-accelerated mice is that their phenotype is multigenic and that the underlying gene mutations are not known. Therefore, we obtained SAMP8 mice from a commercial breeder and phenotypically characterized them. To make the SAMP8 model more suitable for geriatric studies, we performed massively parallel exome sequencing [32] . By applying this method to SAMP8 and SAMR1 mice, we were able to identify 51 SAMP8-specific single nucleotide variants (SNVs), followed by a Polyphen2 analysis that allows phenotype predictions.
MATERIALS AND METHODS

Animals
SAMP8/TaHsd (in short: SAMP8) and SAMR1/ TaHsd (in short: SAMR1) mice were obtained from Harlan Laboratories UK Ltd. They were rederived by embryo transfer followed by expansion of a colony in the SPF unit of our institute's animal facility. Animal experimentation was approved by the Animal Ethics Committee (AEC) of the University of Sydney (approval number K00/1-2009/3/4914).
Phenotypic analysis and histology
The weight of the mice was monitored on a weekly basis. Immunohistochemical staining for glial fibrillar acidic protein (GFAP) was done on 3 m sections of paraformaldehyde-fixed and paraffin-embedded brain tissue of 6 month-old mice as described [33] . More specifically, brains were fixed in paraformaldehyde and embedded in paraffin using an Excalibur tissue processor (Thermo). Antigen retrieval was done in a temperature-and pressure-controlled microwave system (Milestone) in Tris/EDTA pH 9.0 for 7 min at 120 • C, followed by cooling under running tap water for 10 min. Primary antibody anti-GFAP (monoclonal IgG, Sigma, #63893) was diluted 1 : 100 in blocking buffer (heat inactivated 3% normal goal serum, 2% BSA, 0.1% Tween-20 in 1 × PBS) and incubated overnight at 4 • C. After three washes in 1 × PBS, the sections were incubated with an Alexa-coupled secondary antibody (Invitrogen, #A-11001) for 1 h at room temperature, followed by three washes in 1 × PBS. The sections were then mounted in Fluoromount medium (Sigma # F4680) and digital images taken with a BX51 fluorescent microscope (Olympus).
Exome sequencing
Exome enriched, paired end libraries were prepared from genomic DNA of two SAMP8 and two SAMR1 mice following the protocol 'SureSelect Target Enrichment System for Illumina Paired-End Multiplexed Sequencing library' (v1.1.1, November 2010, Agilent). The Illumina Paired-end genomic DNA sample prep kit (PE-102-1001, Illumina) was used for preparing the libraries including end repair, A-tailing, and ligation of the Illumina adaptors. For capture, SureSelect Mouse exome baits (G7550, Agilent) were used to enrich for the mouse exome. Each sample was prepared with an index in an amplification step following capture using the Illumina multiplexing sample preparation oligo-nucleotide kit (PE-400-1001, Illumina). Enriched sample libraries were pooled in equimolar batches of three and each batch run as 100 bp paired end libraries on the Illumina HiSeq 2000 sequencer.
Data analysis
Sequence reads were mapped to the NCBIM37 assembly of the reference mouse genome using Burrows-Wheeler Aligner (http://bio-bwa.sourceforge .net) [34] . Untrimmed reads were aligned allowing a maximum of two sequence mismatches and were discarded where they aligned to the genome more than once. Sequence variants were identified with SAMtools (http://samtools.sourceforge.net) [35] and annotated using Annovar (http://www.openbioinforma tics.org) [36] . A version of PolyPhen2 (http://genetics. bwh.harvard.edu/pph2) [37] , adapted for the mouse, was utilized for the calculation of the variant effect.
Validation of single nucleotide variants
SNVs identified by Next Generation Sequencing were validated using the Amplifluor SNP genotyping system (Chemicon, Millipore). Assays were designed to each SNV of interest and validated against a set of Samp8 and SamR1 mice. Primer sequences for each SNV that has been assayed can be found in the Supplementary Table 1 (available online: http://dx.doi.org/10.3233/JAD-130089).
RESULTS
Phenotypic characterization of SAMP8 mice
To phenotypically characterize SAMP8 mice and differentiate them from SAMR1 mice, we determined the lifespan of both strains. According to Harlan from whom we had obtained the mice, the median survival time of SAMP8 mice is 12.1 months whereas SAMR1 mice have a median survival time of 18.9 months. Others reported a mean lifespan of 9.7 months for SAMP mice (not specifying the sub-strain) and 16.3 months for SAMR mice, while standard inbred mouse strains (such as C57Bl/6) have a life expectancy in the order of 28 months [4] . In agreement with previous data, we found that SAMP8 mice displayed an increased mortality compared to SAMR1 mice (Fig. 1A) , and gained less weight as they aged (Fig. 1B) . At six months of age, using immunohistochemistry, we did not find evidence for amyloid plaque formation in the SAMP8 compared to the SAMR1 mice using the 4G8 antibody, nor did we find pronounced differences in tau phosphorylation using antibodies 12E8, AT180, or AT8 (data not shown). However, what we found at this age was a pronounced astrogliosis in the pons of SAMP8 compared to SAMR1 mice (Fig. 1C) . In the hippocampus, the two strains showed a similar degree of astrogliosis, while cortical areas were, in our hands, virtually free of activated astrocytes (data not shown). Phenotypically, by three to four months of age, SAMP8 mice can be discriminated from SAMR1 mice based on their reduced weight (Fig. 1B) , a slightly hunched position, skin coarseness, and partial alopecia, as shown for 6 month-old mice ( Fig. 2A) .
Exome sequencing of SAMP8 and SAMR1 DNA
To identify genes with a putative role in the SAMP8 phenotype, we performed exome sequencing of two SAMP8 and SAMR1 mice each. Exome enrichment allowed us to successfully sequence 85-90% of the CCDS exome to a high level of coverage. From this sequencing, we found 226 SNVs that were common between the two SAMP8 mice and not seen in either SAMR1 mice or in any previous sequencing effort (>250 exomes, mostly C57Bl/6). By removing olfactory and vomeronasal genes to eliminate a large subset of possible SNV call errors due to the high sequence homology amongst these gene family members, and excluding genes with multiple SNVs (also indicating short-read alignment errors rather than mutations) the list was reduced to 113 SNVs.
Of the 113 SNVs, 105 were selected for validation using a specific Amplifluor assay to each SNV on a larger pool of SAMP8, SAMR1, C57Bl/6, and AKR/J control samples (8 assays could not be designed with primers of sufficient quality). Of the 103 SNVs, 37 were shared with the AKR/J control strain (i.e., a polymorphism between the C57Bl/6 reference genome and the control AKR/J sample), 13 assays failed, 2 were shown to be heterozygous and unique to SAMP8, 1 was a false positive, 1 was homozygous in the SAMP8 strain and heterozygous in all controls, and 51 SNVs were unique to SAMP8 ( of ten), followed by chromosome 13 (five SNVs), and 4, 7, 10, and 19 (with four SNVs each).
Polyphen prediction of SAMP8-specific single nucleotide variants and brain-specific expression of SAMP8 genes
Of the 51 SNVs that we identified as being unique to SAMP8, 10 are possible splice variants (intronic mutations located within 10 base pairs of the exon boundary), while 41 are within the coding sequence. According to the amino acid substitution prediction tool Polyphen2, of the 41 coding variants, 24 are possibly or probably damaging (confidence of 0.5-1.0), while 17 are probably benign (confidence <0.5) ( Fig. 2C ). For the second category (probably damaging SNVs), for three genes, no data are available, four are not expressed in brain, and nine are expressed in brain, ranging from very slight to high expression levels, and from a restricted expression pattern to expression throughout the brain (Fig. 2C) . For the third category (possibly damaging), no data is available for one gene; and 7 genes are listed as being expressed in brain. For the fourth category (benign), for 1 no data are available on brain expression, 5 are not expressed in brain, and 2 are slightly expressed in brain (Fig. 2C) . Overall, the data indicate that at least 50% of all identified genes may have a function in the brain (Fig. 2) . Whether the SNVs cause changes in levels of the encoded proteins, in their subcellular localization, association with other proteins and/or in their activity, remains to be determined in subsequent studies.
DISCUSSION
Characterized by a range of age-associated impairments, which includes the nervous system, senescenceaccelerated SAMP8 mice present themselves as an excellent geriatric model [38] . We confirmed that SAMP8 mice die prematurely and that they display a reduced weight gain compared to SAMR1 mice.
Astrogliosis has been suggested as a useful marker to discriminate, at a pre-symptomatic age, the two strains; however, we found this less reliable as in our studies astrogliosis depended on the brain area investigated, with both strains showing a similar degree of activation in the hippocampus, while SAMR1 mice showed a much lesser degree of astrogliosis in the pons compared to SAMP8 mice.
We also performed exome sequencing and identified 51 SNVs (mutations) that are unique to SAMP8 mice, using senescence-resistant SAMR1 mice as well as the two inbred strains C57Bl/6 and AKR/J (from which SAMR1 and SAMP8 have been originally derived [5] ) as controls. 10 of the SNVs are possible splice variants; 41 are within the coding sequence. Using the prediction tool Polyphen2, we identified 24 of the 51 SNVs as being either probably or possibly damaging. In coming up with these predictions, it is not only the type of amino acid that is critical but also where it sits in relation to the different domains, such as binding and active sites. Interestingly, not all A-T SNVs are benign, as is the case, e.g., for SLC12A4.
As evidenced by GO analysis, the mutated genes encode proteins with a wide range of cellular functions. These include ion transport, cytokine activity, axonogenesis, heme binding, GTP binding, protein transport, and others. 21 of the genes have an OMIM entry and 11 have a reported phenotype in mice with a null mutation. Consulting the Allen brain atlas revealed that a significant fraction is expressed in the brain, often with a regional pattern and ranging from very low to pronounced expression levels. Overall, the data indicate that at least 50% of all identified genes have a function in the brain.
When we analyzed the genes with brain expression in more detail and restricted the analysis to those SAMP8 SNVs for which the Polyphen tool either made no predictions or predicted that they are 'probably or possibly damaging', we identified several gene products that are worth being discussed in the context of the known SAMP8 brain phenotype: APBA3 (also known as Mint3) encodes an adapter protein that is part of the X11 protein family. Interestingly, APBA3 interacts with A␤PP from which A␤ is derived by proteolytic cleavage. More recently APBA3 has been identified as a mediator of A␤PP signaling: Its interaction with a set of transcriptional co-activators was shown to lead to nuclear localization and transactivation, whereas an interaction of the same set with Mint1 or Mint2 prevented nuclear localization and transactivation [39] . There is increasing evidence that in AD gene regulatory networks are deregulated [40] : In the current Table 1 SAMP8-specific mutations and Polyphen predictions. Exome sequencing identified 51 SNVs in the genes indicated that are unique to SAMP8. Mutations were found on all chromosomes (chr) Table 2 SAMP8-specific mutations and gene descriptions. For the 51 SNVs that are unique to SAMP8 the genes are indicated, the UniProt (Universal Protein resource) name, the name of the human ortholog (homolog, where known), the OMIM entry (Online Mendelian Inheritance in Man, where available), as well as a description of the gene Table 3 study, we also identified the enhancer of decapping Edc4 [41] , and Klf12 that encodes Kruppel-like Factor 12, a member of a zinc finger protein family that regulates gene transcription [42] . Interestingly, a recent transcriptomic analysis of tau mutant mice revealed a deregulation of several transcription factors including Zranb1 (a Zinc finger-containing protein) and SFPQ (splicing factor proline/glutamine rich), also known as PSF (Polypyrimidine tract-binding protein-associated Splicing Factor) [43] . Validation of SFPQ revealed that in AD the transcription factor is relocalized from the nucleus to the cytoplasm [43] .
Among the genes with brain expression are several that encode enzymes such as kinases and phosphatases (PTPRD, TESK1, TMEM55B) that could potentially regulate the phosphorylation of cytoskeletal proteins such as tau. TESK1 is particularly interesting as together with Spred1, it is an interaction partner of the kinase MARKK/TAO1 that links the microtubule and actin cytoskeleton [44] . With a SNV in the gene encoding the signal peptidase SPCS2, more fundamental processes could be affected in the SAMP8 mice as depletion of SPC3 in yeast leads to impaired secretion and the accumulation of secretory proteins [45] . TPP1 encodes the lysosomal enzyme tripeptidyl-peptidase 1, and mutations in this gene cause a form of spinocerebellar ataxia, with patients having a shortened lifespan. It might be possible, that the SNV found for TPP in the SAMP8 mice contributes to the shortened lifespan that characterizes the strain [46] . A SNV was also found in the FXN gene, for which a trinucleotide expansion in human causes yet another ataxia, Friedreich ataxia [47] .
Finally, IRS2 (insulin receptor signaling 2) is an interesting molecule with central functions including the regulation of mammalian lifespan and nutrient homeostasis [48] , glucose metabolism [49] , as well as mitochondrial functions and the dealing with oxidative stress [50] . Moreover, IRS2 is a negative regulator of memory formation and has been shown to impair NMDA receptor-dependent long-term potentiation [51, 52] . All of these functions are impaired in the SAMP8 mice suggesting that an impaired IRS2 function could potentially contribute to the SAMP8 phenotype.
Having identified a total of 51 SNVs by exome sequencing that discriminate SAMP8 and SAMR1, we anticipate that these will allow a phenotypic discrimination, especially as it is evident from our list that several of the SNVs are within genes that in principal could contribute to the SAMP8 phenotype. It is reasonable to assume that a subset of the SNVs causes either changes in protein levels, stability, subcellular localization or posttransational modification of the encoded proteins, which can be detected provided that suitable antibodies are available. The SNVs should be also useful in monitoring the SAMP8 strain to ensure that there is no genetic drift in any given colony. Furthermore, it may be possible to establish sub-lines that inherit some of the SNVs and hence result in a segregation of a subset of the phenotypic traits that affect selected systems such as the brain or the immune system.
As mentioned above, SAMP8 mice do not present with typical plaques and tangles, although the accumulation of A␤ and hyperphosphorylated tau has been reported [23, 26] . In order to exploit SAMP8 mice for AD research a further possibility is to cross the SAMP8 mice with either A␤ plaque-forming or tau tangle-forming transgenic mice. Here, for example, the question can be asked whether a tau pathology such as that of P301L tau mutant mice with a memory phenotype [53] or of K369I mutant mice with neuronal loss and a motor phenotype [54, 55] would be accelerated by the presence of distinct SAMP8 SNVs. Alternatively one could ask whether removing or reducing tau would ameliorate some of the phenotypes that characterize the SAMP8 mice [56] . In conclusion, we believe that our data contribute to ascertaining SAMP8 mice as a suitable model system to study aging and dementia.
